Weekly Recap: FY guidance reaffirmed and Astral retirement, $42M charge

ResMed Inc. (NYSE:RMD) reaffirmed fiscal targets while reshaping its device lineup—retiring the Astral platform with a $42M charge and halting new Astral sales in FY27, pivoting NIV to AirCurve S/ST/ST—A on Air11, and closing the $340M Noctrix buy to expand non—invasive RLS offerings.Previous Week…